Acromegaly With Surgical Contraindication Or Inadequate Response Therapeutics
1. Signifor patent expiration
Treatment: NA
Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(12 days ago) | |
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6225284 | RECORDATI RARE | Somatostatin peptides |
Jun, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-34) | Dec 14, 2019 |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 14 December, 2012
Dosage: SOLUTION
More Information on Dosage
SIGNIFOR family patents
